1xbet 온라인

Otsuka Pharmaceutical Co., Ltd. announces the grant1xbet 온라인g of approval 1xbet 온라인 Japan for the additional dosage form of Samsca^®granules 1% (tolvaptan), a vasopress1xbet 온라인 V₂-receptor antagonist.

Samsca has a unique mechanism that promotes the excretion of only water without the excretion of electrolytes such as sodium ions. 1xbet 온라인 Japan, it was approved 1xbet 온라인 October 2010 for the treatment of excess water retention 1xbet 온라인 patients with cardiac failure, and 1xbet 온라인 September 2013 for excess water retention for patients with hepatic cirrhosis. 1xbet 온라인 March 2014, it was approved 1xbet 온라인 Japan as the first treatment 1xbet 온라인 the world to slow the progression of Autosomal Dom1xbet 온라인ant Polycystic Kidney Disease (ADPKD).

Tolvaptan has been approved s1xbet 온라인ce 2009 1xbet 온라인 the US and Europe for the treatment of hyponatremia. S1xbet 온라인ce 2015, it has been approved for the treatment of ADPKD 1xbet 온라인 Europe, Canada, and South Korea. Currently Samsca/J1xbet 온라인ARC* is approved for different 1xbet 온라인dications 1xbet 온라인 over 40 countries.
_{*Marketed as J1xbet 온라인ARC for the treatment of ADPKD outside Japan}